VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY IN ELDERLY PATIENTS AND THOSE WITH CONTRAINDICATIONS FOR ANTI-TNF THERAPY: A REAL-WORLD, NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Mohamed Attauabi  1     Camilla Höglund  2     Janne Fassov  3     Kenneth Bo Pedersen  4     Heidi Bansholm Hansen  5     Signe Wildt  6     Michael Dam Jensen  7     Anders Neumann  8     Cecilie Lind  8     Henrik Albæk Jacobsen  9     Ana-Maria Popa  10     jens kjeldsen  11     Natalia Pedersen  12     akbar molazahi  13     Kent Haderslev  14     Claus Aalykke  14     Torben Knudsen  14     Wojciech Cebula  14     Pia Munkholm  14     Flemming Bendtsen  15     Jakob Benedict Seidelin  15     Johan Burisch  15    
1 Herlev Hospital, Herlev, Denmark
2 OUH Svendborg Hospital, Svendborg, Denmark
3 Aarhus University Hospital, Aarhus, Denmark
4 Hospital of South West Denmark, Esbjerg, Denmark
5 North Zealand University Hospital, Frederikssund, Denmark
6 Zealand University Hospital, Koege, Denmark
7 Lillebaelt Hospital, Vejle, Denmark
8 Regional Hospital Viborg, Viborg, Denmark
9 Aalborg University Hospital, Aalborg, Denmark
10 Nykoebing Falster Hospital, Nykoebing Falster, Denmark
11 OUH Odense University Hospital, Odense, Denmark
12 Slagelse Hospital, Slagelse, Denmark
13 Holbaek Hospital, Holbaek, Denmark
14 Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
15 Copenhagen University Hospital, Hvidovre, Denmark

Topic
IBD

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing